Impact of comorbidities on the treatment of non-Hodgkin’s lymphoma: a systematic review

References

• Sant M, Allemani C, Tereanu C, et al. AEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116:3724-34
   PubMed Web of Science ®Google Scholar
• Smith A, Howell D, Patmore R, et al. Incidence of hæmatological malignancy by sub-type: a report from the Hæmatological Malignancy Research Network. Br J Cancer 2011;105:1684-92
   PubMed Web of Science ®Google Scholar
• Fisher RI, Miller TP, O’Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004;2004:221-36
   Google Scholar
• Komrokji RS, Al Ali NH, Beg MS, et al. Outcome of diff use large B-cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk 2011;11:257-60
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7
   PubMed Web of Science ®Google Scholar
• van Spronsen DJ, Janssen-Heijnen MLG, Breed WP, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Ann Hematol 1999;78:315-19
   PubMed Web of Science ®Google Scholar
• Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441-7
   PubMed Web of Science ®Google Scholar
• Read WL, Tierney RM, Page NC, et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004;22:3099-103
   PubMed Web of Science ®Google Scholar
• Janssen-Heijnen MLG, van Spronsen DJ, Lemmens VE, et al. A population-based study of severity of comorbidity among patients with non-Hodgkin’s lymphoma: prognostic impact independent of international prognostic index. Br J Haematol 2005;129:597-606
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) Statement: guidelines for reporting observational studies. PloS Med 2007;4:e296
   PubMed Web of Science ®Google Scholar
• Varga C, Holcroft C, Kezouh A, et al. Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population-based study. Leuk Lymphoma 2014;55:533-7
   PubMed Web of Science ®Google Scholar
• Huntington SF, Talbott MS, Greer JP, et al. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leuk Lymphoma 2012;53:1461-8
   PubMed Web of Science ®Google Scholar
• Meguro A, Ozaki K, Sato K, et al. Rituximab and 70% cyclophosphamide, doxorubicin, vincristine and prednisone forJapanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma 2012;53:43-9
   PubMed Web of Science ®Google Scholar
• van der Poel MW, mulder WJ, Ossenkoppele GJ, et al. Comorbidity and treatment decision-making in elderly non-Hosgkin’s lymphoma patients: a survey among haematologists. Neth J Med 2014;72:165-9
   Google Scholar
• Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol 2014;165:489-96
   PubMed Web of Science ®Google Scholar
• van de Schans SA, Wymenga AN, van Spronsen DJ, et al. Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 2012;23:1280-6
   PubMed Web of Science ®Google Scholar
• Lin TL, Kuo MC, Shih LY, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 2012;91:1383-91
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Miura K, Hojo A, et al. Charlson comorbidity index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 2011;137:1079-84
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Gleeson M, Mikhael J, et al. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer 2012;118:6079-88
   PubMed Web of Science ®Google Scholar
• Winkelmann N, Petersen I, Kiehntopf M, et al. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011;137:733-8
   PubMed Web of Science ®Google Scholar
• Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large B cell lymphoma patients who benefit from aggressive therapy. Cancer 2009;115:4547-53
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Rossi G, et al. Outcome of frail elderly patients with large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leuk lymphoma 2014;55:38-43
   PubMed Web of Science ®Google Scholar
• Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 2012;17:838-46
   PubMed Web of Science ®Google Scholar
• Trebouet A, Marchand T, Lemal R, et al. Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Ann Oncol 2013;24:2612-18
   PubMed Web of Science ®Google Scholar
• Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (≥ 80 years) non-Hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 2011;156:196-204
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Frigeri F, Arcamone M, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy. Br J Haematol 2011;154:579-89
   PubMed Web of Science ®Google Scholar
• Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 2013;32:282-7
   PubMed Web of Science ®Google Scholar
• Pollack SM, Steinberg SM, Odom J, et al. Assessment of the hematopoietic cell transplantation comorbidity index in non-hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:223-30
   PubMed Web of Science ®Google Scholar
• Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009;23:1131-8
   PubMed Web of Science ®Google Scholar
• Wildes TM, Augustin KM, Sempek D, et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:840-6
   PubMed Web of Science ®Google Scholar
• Plattel WJ, Kluin-Nelemans HC, de Bock GH, van Imhoff GW. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant 2011;46:827-34
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Miller MD, Paradis CF, Houk PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of cumulative illness rating scale. Psychiatry Res 1992;41:237-48
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-19
   PubMed Web of Science ®Google Scholar
• Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008;112:1992-2001
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Martin P, Hurtado Rua S, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol 2012;87:433-5
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 2004;104:961-8
   PubMed Web of Science ®Google Scholar
• Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23:455-68
   PubMedGoogle Scholar
• Guralnik JM. Assessing the impact of comorbidity in the older population. Ann Epidemiol 1996;6:376-80
   PubMed Web of Science ®Google Scholar
• van den Akker M, Buntinx F, Metsemakers JF, et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998;51:367-75
   PubMed Web of Science ®Google Scholar
• de Groot V, Beckermann H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003;56:221-9
   PubMed Web of Science ®Google Scholar